🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)

Recruitingn/aAges 18 Years - anyAllUniversity of South China
NCT04889053 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Coronary artery calcification (CAC) is a common complication of type 2 diabetes mellitus(T2DM), which can significantly increase all-cause mortality and the incidence of serious cardiovascular events, and increase the burden of the national economy. The epidemiological characteristics and the clinical progress of CAC are still not clear. Moreover, the pathogenesis of CAC has not yet been fully elucidated, and lack of specific diagnostic indicators. Arterial calcification is an active, reversible, and multifactorial biological process like bone formation. It is generally believed that early detection of calcification lesions and active targeted treatment may be the key to prevention and treatment of vascular calcification. In addition, statins are commonly used in patients with dyslipidemia and can stabilize CAC plaque. However, the timing, dosage and effect of statins are controversial.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years old * Type 2 diabetes is diagnosed according to WHO diagnostic criteria * Low dose prospectively triggered sequential dual-source CT coronary angiography can be performed at baseline investigation * Those subjects are able to understand the purpose and procedure of this study and sign the informed consent voluntarily Exclusion Criteria: * Those have received coronary artery stenting or coronary artery bypass grafting * Those with severe lung (respiratory failure), liver (ALT or AST 3 times normal value or bilirubin increase), renal dysfunction\[GFR \< 45ml/(min.1.73m2) or dialysis patients * Malignant tumor * Mental illness or mental retardation * Pregnant or lactating women or those with fertility planning * Concomitant diseases (hyperparathyroidism, sarcoidosis, amyloidosis) affecting calcium balance and soft tissue calcification * Contraindications of contrast agents * Based on the judgment of the researcher, the compliance is poor and the study could not be completed according to the requirements
💊

What it tests

  • Not listed
📍

Where

1 site
The First Affiliated Hospital of University of South China
Hengyang, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy